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Abstract Tumor necrosis factor-alpha (TNF-a)i sa
principal mediator in pro-inﬂammatory processes that
involve necrosis, apoptosis and proliferation. Experimental
and clinical evidence demonstrate that peripheral nerve
injury results in activation and morphological changes of
microglial cells in the spinal cord. These adjustments occur
in order to initiate an inﬂammatory cascade in response to
the damage. Between the agents involved in this reaction,
TNF-a is recognized as a key player in this process as it not
only modulates lesion formation, but also because it is
suggested to induce nociceptive signals. Nowadays, even
though the function of TNF-a in inﬂammation and pain
production seems to be generally accepted, diverse sources
of literature point to different pathways and outcomes. In
this review, we systematically searched and reviewed
original articles from the past 10 years on animal models of
peripheral nervous injury describing TNF-a expression in
neural tissue and pain behavior.
Keywords TNF-a  Central sensitization  Neuropathic
pain  Preclinical studies  Neuroinﬂammation
Introduction
Neuropathic pain (NP) is a chronic and extensive condition
secondary to dysfunction or nerve damage, usually origi-
nated in the periphery. If the injurious stimulus perpetuates,
dorsal horn neurons in the spinal cord become sensitized,
enduring pain perception; process known as central sensi-
tization (CS) [1–3]. Because inﬂammation is essential for
NP development and that apoptosis is involved in CS,
tumor necrosis factor-alpha (TNF-a) becomes an interest-
ing study target [4, 5]. Several studies have investigated the
relation between TNF-a expression in different nervous
tissues and pain behavior; hitherto these studies have not
been conclusive. Though in general, TNF-a is associated
with cellular harm and pain behavior, it has also been
shown that these effects are bound by temporal and spatial
resolutions.
For decades, animal models have reproduced cardinal
aspects of human pain, offering essential features for the
preclinical study of NP. The main classiﬁcation of NP
models divides them into central pain, peripheral nerve
injury, and secondary disease neuropathy models. In this
review, we will focus on the peripheral nerve injury models
in order to study the effect of these lesions on the process
of central sensitization. The primary anatomical structures
involved in these injury procedures are the sciatic nerve
and dorsal root ganglion (DRG). These methods comprise
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DOI 10.1007/s10072-011-0599-zpartial ligature, complete ligature, root or nerve pinching,
crushing, transection, and local inﬂammatory stimulus. The
most representative examples include the chronic con-
striction injury model (Bennett model), partial sciatic nerve
ligation model (Seltzer model), spinal nerve ligation,
plexus avulsion, compression of the DRG/root, laminec-
tomy, and disc injury [6–12].
TNF-a is considered to be one of the principal medi-
ators in pro-inﬂammatory processes that involve necrosis,
apoptosis and proliferation [5, 13–15]. It is produced
essentially by macrophages and T-lymphocytes in
response to stressed or damaged tissue, and it may
therefore serve as a systemic marker for tissue injury. For
instance, complications found in inﬂammatory and auto-
immune diseases are often accompanied by increased
serum levels. In case of increased levels, a systemic
inﬂammatory reaction leading to septic shock might
occur. However, if TNF-a is present in low quantities it
would generate a process responsible for local inﬂam-
matory symptoms, depending on the damaged structure
[16–18]. In the nervous system, when a local peripheral
injury is produced, it generates activation and morpho-
logical changes in dorsal horn microglia [19–23]. This
process includes P2X4 receptors activation, followed by
Ca
2? inﬂux and p38 MAPK activation. As a consequence,
microglia releases diffusible factors like TNF-a, modify-
ing neuronal excitability and thereby pain perception
[24–26]. TNF-a has two distinct receptors, TNF receptor-
1 (TNFR1 or p55) and TNF receptor-2 (TNFR2 or p75).
The main effect of TNFR1 is related to apoptosis and is
present in practically every cell; whereas TNFR2 has a
limited constitutive expression and is basically associated
with cell survival [27, 28]. This is particularly important
in pain attributable to different effects depending on
speciﬁc receptor activation [29–31].
In this review, we present the functional and biochem-
ical changes after peripheral nerve injury in animal models,
focused on the role of TNF-a in the development of NP.
Search methods
Articles were collected via PubMed from 1999 until July
2010; in order to analyze the understanding progress in the
last decade, a period with increased standardized methods
since the initial works associating TNF-a and neuropathic
pain were performed. The following keywords and their
combinations were used: chronic neuropathic pain, tumor
necrosis factor, dorsal horn apoptosis, central sensitization,
peripheral nerve injury, and neuropathic pain model. The
obtained citations were examined by two independent
reviewers in order to assure the application of the inclusion
and exclusion criteria.
The inclusion criteria were: original full-text articles,
preclinical reports, written in English, quantitative data on
inﬂammatory response and pain production, mechanical
compression or irritation to neural tissue, involvement of
peripheral nervous system injury, and detailed measure-
ment instrument with objective examination protocol. The
exclusion criteria comprised: omission of TNF-a levels
measurements, absence of standardized behavioral evalu-
ations, presence of co-morbidity, use of TNF-a as inductor
of lesion or inﬂammatory procedure, trauma-related or
spinal cord injury models, and involvement of other
cytokines.
Results
From the primary search a total of 2,896 publications were
identiﬁed. Based on titles and abstracts, 2,814 articles were
discarded due to irrelevance to the topic or duplication
between different combinations. From the 82 prospective
studies, 73 were selected according to the inclusion criteria.
After applying the exclusion criteria we obtained 33
articles that were ﬁnally chosen for this review (Fig. 1)
[32–64].
From these 33 studies, 25 used rats of different strains
and 8 applied genetically modiﬁed mice. The sample size
of the experiments ranged from 7 to 360 animals, with a
mean of 77 rodents per study. The most reproduced model
Fig. 1 Flow diagram representative of search strategy, identiﬁcation,
inclusion and exclusion of articles
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123was the ligation of the sciatic nerve denominated chronic
constriction injury (n = 14), followed by nerve crushing
(n = 8) and nerve transection (n = 4). The most common
location to induce the inﬂammatory process was the sciatic
nerve (n = 18) followed by the spinal nerves (n = 5).
Tissue samples were obtained from diverse structures,
mostly the DRG (n = 16), sciatic nerve (n = 13) and
spinal cord (n = 10) (Table 1). Laboratory techniques used
for TNF-a determination in these biopsies included pri-
marily immunohistochemistry (n = 22), and secondary
ELISA (n = 8), qPCR (n = 7), and immunoblotting
(n = 5). Follow-up of pain behavior monitoring ranged
from 5 days to 12 weeks, 14 days being the most repeated
period (n = 11). Not all of the included studies in this
review applied behavioral testing related to allodynia and
hyperalgesia (n = 11); the rest assessed mechanical sen-
sitive thresholds primarily with von Frey ﬁlaments
(n = 18), and thermal responsiveness with the Hargreaves
test (n = 10). Some other conduct assessment techniques
comprising hot-plate (n = 2) and Randall–Selitto tests
(n = 2).
Mechanical allodynia was assessed in 20 studies through
application of pressure in affected and non-affected limbs
in order to evaluate painful responses. Each one of these
studies showed a signiﬁcant decrease in all cases in noci-
ceptive thresholds as a consequence of the injury procedure
when compared to sham groups. Initiation of pain typically
started 24 h after the lesion intervention, reached maxi-
mum levels at 1–2 weeks, and returned close to presurgical
control levels after 4 weeks. In two reports bilateral allo-
dynia was present, in one case only for 7 days and referred
in the second one as signiﬁcant and long-lasting [42, 64].
Nine articles evaluated pharmacotherapy and found the
highest effectiveness when the drugs were applied within
7 days after injury. In a speciﬁc case of cannabinoid
administration, an antinociceptive effect was achieved
after applying high doses from day 7 to 14 after injury
(20 mg/kg) [36]. Opioid administration also reverted suc-
cessfully the acute nociceptive effects, but only at
increased doses and tolerance development (10 mg/kg
b.i.d. for 5 days) [55].
Thermal hyperalgesia followed a similar pattern as
mechanical allodynia, showing lower thresholds at short-
term measurements, starting to decrease and even reaching
baseline levels after 14 days. In one article TNFR1-deﬁ-
cient rodents did not exhibit signiﬁcant painful behavior
after heating stimulation at any time point after injury [63]
(Table 2).
All models show increased TNF-a levels after injury.
Pharmacological treatments that failed to decrease these
levels included monotherapy of paracetamol, tramadol,
cannabidiol, morphine, soluble TNF receptor, and IL-1
receptor antagonist. On the other hand, successful
interventions that lower TNF- a expression included
NMDA receptor antagonist MK-801, thalidomide, com-
bined therapy of soluble TNF receptor with IL-1 receptor
antagonist, chronic administration of morphine (dose-
dependant with aggravation after interruption), a2-macro-
globulin, nimesulide, a combination of paracetamol with
tramadol, recombinant human erythropoietin and triam-
cinolone [32, 34–36, 43, 45, 55, 61, 62, 64].
Chronologically, TNF-a expression was characterized
by an immediate increase in affected structures starting as
soon as 1 h after injury [45, 56, 59]. Peak levels are
detected around 24 h, sustain for about 3 days, and in
many cases then decreased, occasionally to baseline levels
[40, 41, 45, 47]. Some publications describe a lowering of
TNF-a expression after this point, but the mainstream
pointed out the maintenance of a plateau phase up to
1–2 weeks, followed by a periodical decline. Measure-
ments performed at 3 and 4 weeks reveal weak signaling of
the inﬂammatory process [37, 39–41, 45, 47, 54, 56, 59,
60]. Only one study documented prolonged increased TNF-
a levels lasting at least 6 and 12 weeks, not only in nervous
tissue but also in connective tissue, after applying the high
force reaching task model [39].
The degree to which an altered TNFR1 and TNFR2 ratio
contributes to pain behavior is still not clear. One study
observed an increased TNFR1 expression several days after
dorsal root lesion, while TNFR2 levels remained unchan-
ged [44]. In contrast, a similar follow-up after sciatic nerve
injury resulted in a twofold increased TNFR1 level and a
sevenfold elevated TNFR2 level [41]. Yet another report
showed that immediate measurement only after 6 h post-
spinal nerve ligation revealed that both receptors showed
similar increased expression in the dorsal root ganglia and
remained at comparable levels up to the maximum follow-
up [59].
Discussion
In this review we have summarized the reports that
appeared over the past 10 years and described peripheral
injury-induced TNF-a expression in the nervous tissue and
its role in the production of CS. To date, there is a con-
siderable amount of evidence to support the hypothesis that
inﬂammatory process following tissue damage can lower
pain thresholds. In this respect, many pathways and cyto-
kines have been described to contribute in the development
of chronic nociceptive signaling, including the three pro-
inﬂammatory cytokines that induce activation of p38
MAPK: TNF-a, IL-1b and IL-6 [25]. Focus on TNF-a is
because it is regarded as the archetypical proinﬂammatory
agent, attributable to its function as an inductor of diverse
processes that initiate and perpetuate the inﬂammatory
Neurol Sci (2011) 32:757–771 759
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123Table 2 Detection methods to asses TNF-alpha expression and behavioral tests to measure pain
Study
no.
TNF detection method and
behavioral test
TNF-a levels Pain behavioral data
1 Immunohistochemistry and
qPCR
Ninefold increase of TNF-a mRNA in control
animals. a2-macroglobulin activated for cytokine
binding decreases levels of mRNA expression
after injection
None
2 ELISA and Hargreaves test Signiﬁcant increase of TNF-a levels in the hindpaw
and forepaw at all time-points compared with
control animals after formalin injection
Signiﬁcant hyperalgesic hindpaw response after
formalin administration, but not in the forepaw
3 ELISA and Randall–Selitto
paw-withdrawal test
TNF-a levels signiﬁcantly increased in non-treated
animals. TNF-a concentrations prevented with
nimesulide or paracetamol and tramadol
combined, but not by paracetamol and tramadol
used independently
Signiﬁcant decrease of nociceptive thresholds in
non-treated animals. Mechanical allodynia was
prevented by oral administration of nimesulide,
tramadol and paracetamol
4 Immunohistochemistry,
histology, qPCR, von Frey
ﬁlaments and Hargreaves
test
TNF-a was present in endoneurial cells, including
macrophages, axons and Schwann cells cytoplasm
in non-treated animals. rhEpo decreased TNF-a
mRNA at injury site, and also decreased the extent
of nerve degeneration
Signiﬁcant mechanical allodynia and thermal
hyperalgesia increased in non-treated group, but
signiﬁcantly decreased after rhEpo
administration
5 ELISA, Randall–Selitto paw-
withdrawal test and
Hargreaves test
Increased TNF-a levels were present in injured
DRG when compared to sham, but no changes in
injured sciatic nerve rats. High doses of
cannabidiol did not modiﬁed the elevated levels
present in DRG samples
Signiﬁcant increase in mechanical and thermal
hyperalgesia in non-treated group; attenuated
both by cannabidiol, but with dose-dependent
behavior and only after using high doses
6 Immunohistochemistry, in
situ hybridization, bioassay
and hot-plate test
Increased TNF-a levels in sciatic nerve until day 14,
and dissipated after that, with unchanged levels in
contralateral nerve; thoracolumbar spinal cord
showed elevated TNF-a levels; no elevation in
cervical spinal cord; signiﬁcant accumulation
increase of mRNA speciﬁc for TNF-a in locus
coeruleus
Signiﬁcant decrease of paw-withdrawal latency
when compared to sham and control, with
highest value on day 12 and return to baseline
levels on day 14
7 Immunohistochemistry Increased TNF-a levels in neuronal bodies and
satellite cells compared to control and sham rats
(ipsi- and contralateral, but higher in contralateral
side). Levels reached highest peak 1 week after
surgery, decreasing after 2 weeks; with TNFR1
expression ipsi- and contralateral after 2 weeks
None
8 ELISA and von Frey
ﬁlaments
Increased TNF-a levels at week 6, but not
signiﬁcant at week 12 in serum. High levels
detected in distal bone at week 12 after repetitive
task performance
Withdrawal threshold decreased progressively at
weeks 6 and 12 for cutaneous sensitivity and grip
strength at week 12
9 Immunohistochemistry,
Immunoblotting and ELISA
TNF-a levels increased rapidly after CCI with
highest peak at 12 h, up to day 3. Rapid increase
of endoneurial TNF with plateau phase back to
baseline on day 14
None
10 ELISA, von Frey ﬁlaments
and Hargreaves test
TNF was increased on day 1 and 3 after injury (CCI
and crush) but it was not detectable on day 7 or
after. TNFR1 increased twofold between days 1
and 7; and TNFR2 elevated sevenfold on days 3
and 7
Thermal hyperalgesia and mechanical allodynia
are present in both CCI and crush; thermal
sensitivity maximum peak on week 2, and
mechanical allodynia throughout all measures
11 Immunohistochemistry,
immunoblotting and von
Frey ﬁlaments
TNF-a expression in the contralateral DRG
signiﬁcantly increased from day 7 to 21
Ipsilateral withdrawal threshold was signiﬁcantly
decreased for 21 days; contralateral threshold
decreased also, but for 7 days
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123Table 2 continued
Study
no.
TNF detection method and
behavioral test
TNF-a levels Pain behavioral data
12 Immunohistochemistry, von
Frey ﬁlaments, hot-plate test,
pin-prick test and acetone drop
test
TNF-a staining was signiﬁcantly increased after
injury; especially prominent in Schwann cells
and cells with cytological mast cells
characteristics. TNFa-positive mast cells
signiﬁcant reduction after triamcinolone
administration
Signiﬁcant increase in heat-hyperalgesia,
mechano- and cold-allodynia throughout the
tests. Triamcinolone had a signiﬁcant reduction
on mechanical allodynia and thermal
hyperalgesia
13 Immunohistochemistry and
histology
Presence of constitutive TNFR1 on DRG, spinal
afferences, solitary tract, vagal and spinal
trigeminal tract in naive and operated animals.
No TNFR2 shown in the solitary tract or dorsal
horn afferences.
None
14 Immunohistochemistry,
immunoblotting and von Frey
ﬁlaments
1 h after the injury, TNF immunoreactivity was
shown in Schwann cells, endothelial cells,
ﬁbroblasts and intact axons. Increasing
expression until a peak at 48 h; after that at 96 h
very weak activity.
Mechanical hyperalgesia was detected from 6 to
12 days after injury. Etanercept inhibited pain
related behaviors signiﬁcantly
15 qPCR TNF-a levels remained unchanged in
contralateral nerves. Signiﬁcant ipsilateral
increase at day 3 in TNF-a levels
None
16 qPCR, von Frey ﬁlaments and
Hargreaves test
TNF-a, TNFR1 and TNFR2 mRNA levels in
ipsilateral DRG increased signiﬁcantly after
1 day post-injury, levels decreased after day 1,
and returned to baseline on days 7 and 14; in the
spinal cord the maximal level of TNF-a and
TNFR1 was reached on day 3, and also
decreased to baseline at days 7 and 14
Mechanical allodynia increased signiﬁcantly
1 day after injury with maximum levels at day
7. Thermal hyperalgesia had its peak at day 3.
Both persisted for at least 28 days
17 Immunohistochemistry and von
Frey ﬁlaments
Signiﬁcantly higher TNF-a cells and average
staining intensity compared to sham
Threshold signiﬁcantly reduced when compared
to sham group
18 Immunohistochemistry Signiﬁcantly higher cells in disc incision group
compared to sham
None
19 Immunohistochemistry and
histology
Signiﬁcant increase of TNF-a immunoreactive
cells between day 1 and 3, medium levels at
days 7 and 14, and very decreased on day 21.
No cells found after TNF-a inhibitor treatment
at any time point
None
20 Immunohistochemistry and
electron microscopy
Signiﬁcant increase pixels in endoneurium and
inﬂammatory crescent
None
21 Immunohistochemistry Weak to moderate immunoreactivity in DRG
when compared to non-lesion groups. Increased
immunoreactivity in spinal cord with its highest
peak after 5 days
None
22 qPCR, von Frey ﬁlaments and
Hargreaves test
Gene expression statistical signiﬁcance only at
day 14
CCI group showed reduced sensory threshold for
thermal and mechanical allodynia (mainly at
short-term periods)
23 Immunohistochemistry,
immunoblotting and von Frey
ﬁlaments
Immunohistochemistry colocalized TNF-a with
endoneurial macrophages and GFAP-IR glial
cells. Immunoblotting showed signiﬁcant
expression on day 7 in the NP group, but any
difference at day 28
Threshold signiﬁcantly reduced in NP group with
lowest point at day 14, with gradual increase
after it
24 Immunohistochemistry, ELISA,
von Frey ﬁlaments and tail-
ﬂick test
High amounts of cytokines and mRNA expression
after spinal nerve transection, with no effect of
acute morphine administration, tolerance with
chronic treatment and worsening with
withdrawal
Signiﬁcant increase of allodynia in both tests,
reverted effect in both with opioids application
(high doses)
25 qPCR, von Frey ﬁlaments and
Hargreaves test
High levels of mRNA in the sciatic nerve at 6 and
24 h; in DRG at 24 and 72 h; and no expression
at any moment in spinal cord
CCI group showed reduced sensory threshold for
thermal and mechanical allodynia (lowest point
at day 14)
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123response. At the same time, its increased expression in
nervous tissues upon a pain stimulus suggests that this
cytokine is essential for the development of pain sensation
[65–69].
Several authors published similar results with regard to
TNF-a presence in peripheral and central nervous tissue
after neural injury (Fig. 2). However, part of the main
divergences remains in the involvement and interactions of
TNFR1 and TNFR2. Thus far, it seems that both receptor
types play a different role in the development of allodynia
and hyperalgesia depending on the site of the lesion and the
moment of the cascade activation. For example, TNFR1
has shown constitutive expression in the uninjured spinal
cord in modulatory centers like the dorsal horn, whereas
these areas hardly express TNFR2 [44, 70]. Nevertheless,
this does not imply that after peripheral nerve injury and
Table 2 continued
Study
no.
TNF detection method and
behavioral test
TNF-a levels Pain behavioral data
26 Immunohistochemistry Weak cell expression of TNFR1 in non-injured
neurons; elevated immunoreactivity for TNFR1
in injured neurons. Higher receptor expression in
higher levels of DRGs compared to lower spinal
levels.
None
27 Immunohistochemistry, von
Frey ﬁlaments and
Hargreaves test
Immunohistochemistry showed no statistical
differences between treated and untreated
animals after 10 days (no differences between
treatments)
Signiﬁcant increase of mechanical and thermal
allodynia in CCI group (anti-TNF Ab reduces
thermal hyperalgesia)
28 Immunohistochemistry and von
Frey ﬁlaments
Low levels of TNFR1 and TNFR2 in sham
animals. Increased expression of both receptors
after 6 h of lesion, with a second peak at 5 days.
Uninjured DRG showed early TNFR1
expression similar to ligated DRGs animals
Signiﬁcant mechanical allodynia showed in
ligated animals when compared to sham, starting
at 6 h with a peak at 24 h
29 Immunohistochemistry,
Immunoblotting and von Frey
ﬁlaments
Immunoblotting showed signiﬁcant expression in
the distal crush group at every time-point
(always higher than any other group). Proximal
crush group showed signiﬁcance on days 2, 7
and 14. Both groups indicated signs of apoptosis
in stainings
At day 14 proximal and distal crush groups
showed reduced thresholds; at day 28 only the
distal crush group showed signiﬁcant
mechanical allodynia
30 Immunohistochemistry, ELISA
and von Frey ﬁlaments
Moderate to intense activation expression in the
spinal cord of all animals, any treatment showed
to be effective to change these ﬁndings
Signiﬁcant increase of allodynia in saline treated
rats, high response rate when treated with
sTNFR
31 qPCR mRNA was detectable in controls in all studied
tissues. Gene expression decreased within the
ﬁrst 6 h after surgery in all areas. NMDA
receptor antagonist inhibited early gene
expression decrease
None
32 Histology, Electrophysiology,
von Frey ﬁlaments,
Hargreaves test and cold
sensitivity test
TNFR1(-) mice showed signiﬁcant increase of
intact axons on day 36 compared to wild-type
mice. Maximal signiﬁcant edema was found on
day 3 in TNFR2(-) mice, but also the lowest
signiﬁcant level at day 15 in this same group. No
differences found in number of macrophages
and degenerating ﬁbers
TNFR1(-) mice did not develop heat allodynia.
TNFR1(-) and TNFR2(-) mice showed
decreased mechanical and cold hyperalgesia;
and less changes in skin temperature
33 Immunohistochemistry, von
Frey ﬁlaments and
Hargreaves test
Signiﬁcant increase in immunoreactivity cells of
TNF-a and TNFR1 in ipsilateral DRG compared
to sham; and increased expression of TNF-a and
TNFR1 bilaterally in dorsal and ventral horn of
the spine. Signiﬁcant decrease in
immunoreactivity was found in DRG and spinal
cord after thalidomide injection at any time
point of evaluation after surgery
Signiﬁcant and long-lasting bilateral mechanical
allodynia and thermal hyperalgesia in
transection group. Thalidomide injection
attenuated both types of allodynia when it was
applied in the ﬁrst 7 days post-surgery
CCI chronic constriction injury, rhEpo recombinant human erythropoietin, DRG dorsal root ganglion, NP nucleus pulposus, sTNFR soluble TNF
receptor, TNFR1(-) deﬁcient TNF receptor 1, TNFR2(-) deﬁcient TNF receptor 2, TNFR1 TNF receptor 1, TNFR2 TNF receptor 2, GFAP-IR
glial ﬁbrillary acidic protein-immunoreactive
764 Neurol Sci (2011) 32:757–771
123TNF-a release, TNFR2 could not be involved in nocicep-
tive regulation [47]. This could also be dependant on the
proximity of these lesions from the spinal cord, illustrated
by earlier manifestation of pain in spinal nerve lesions
(h) than in sciatic nerve lesions (days) [45, 59]. In judg-
ment of the literature reported to our days, it is not still
clear if the ﬁnal nociceptive outcome is more dependant on
the amount of cytokine or on the activation/inhibition of
speciﬁc receptors (Fig. 3).
The increase of TNF-a immunoreactive cells or mRNA
levels showed a similar temporal resolution, regardless of
the studied tissue or injury model. As previously described,
TNF-a production typically starts to reach maximal levels
within 24 h, which are maintained for over 2 weeks and
then usually drop [37, 39–41, 45, 47, 54, 56, 59, 60]. This
paradigm is important for understanding the development
of painful symptomatology and for the therapeutic timing
approach. Behavioral data show that the clinical
presentation follows the presence of increased amounts of
TNF-a in neural tissue [71–73]. Fluctuation in TNF-a
levels tended to match with increased or decreased states of
mechanical allodynia and thermal hyperalgesia. Progres-
sive nociception in injured animals was established after
the ﬁrst few days and maintained until its highest point
around the second week, followed by a gradual drop up to
baseline thresholds [37, 54, 56]. This transient pain
behavior may be a consequence of the continuous adapta-
tion of pain perception that familiarizes the animal with the
applied stimuli, yet in each study the cytokine levels cor-
related closely to the pain sensation [41, 53]. In this
respect, TNF-a involvement in pain could also be inferred
in studies where wild-type mice showed greater levels of
pain when compared to genetically TNF knock-out animals
[74, 75].
The pharmacological therapies proved to be successful
when applied during the ﬁrst 7 days post-lesion, which is
Fig. 2 Mechanisms involved in pain. TNF-a increases hyperexcit-
ability and consequently neuropathic pain via different peripheral and
central mechanisms. At the site of injury TNF-a leads to activation of
p38 and JNK, followed by increased TTX-R and VR1 expression,
accompanied by production of other inﬂammatory agents and
substance P. In the dorsal horn of the spinal cord, TNF-a induces
increased activity of NMDA and AMPA receptors, leading to
depolarization. It is not completely elucidated yet the role of
TNF-a on inhibitory neurons, but it is suggested that it increases
GABA and glycine release from presynaptic terminals, producing
hyperexcitability
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123consistent with the temporal resolution of TNF-a expres-
sion, probably avoiding the initial inﬂammatory response
[66, 76]. This is also an essential matter in the apparent
dual intervention of TNF-a in neurons as toxic or protec-
tive agent. Originally, the function of this cytokine has
been described as harmful, but previous evidence and data
in this review suggest that protection and regeneration
could be involved in a receptor-dependant mode. It has
been described that TNFR2 has a fundamental participation
in remyelination of neurons after injury, probably linked to
its late participation in the inﬂammatory cascade [44, 70,
77–79]. This suggestion also comes from delayed expres-
sion of TNFR2, which coincides with behavioral recovery
in the late phases of pain sensation. Thus, it is of vital
Fig. 3 Intracellular pathways
related to TNFR1 and TNFR2.
On the left, TNFR1 is primarily
related to the induction of
apoptosis; though, it can interact
via TRAF2 to promote cell
survival under certain
circumstances. On the right,
TNFR2 function is oriented to
follow parallel pathways that
will lead to cell survival and
proliferation. Probably the
balance and interaction between
these two receptors determine
the ﬁnal damage produced by
lesions, and therefore the
amount of pain
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123importance to understand the temporal expression of TNF-
a and its receptors in order to develop a successful thera-
peutic strategy. In these days, we can observe that the same
cytokine at different moments, acting on different recep-
tors, could bring opposite histological and clinical out-
comes. These observations bring the query as to which
factors are more determinant for the production of pain, the
concentration of TNF-a or the TNFR1–TNFR2 expression
ratio. In this respect, a key question that remains is why
patients with chronic NP do not beneﬁt from this self-
limiting protective mechanism. We believe that a balance
alteration between the TNF-a receptors could determine
the severity of pain, not only in a temporal expression (acute
orchronic)butalsoontheextensionoftheproduceddamage.
Animal models have proven to develop and reproduce pain
inacomparablemannertohumanobservations.Insummary,
there is evidence from physical injury models, transgenic
models, and pharmacological interference studies that TNF-
a expression in the spinal cord modulates pain sensation.
However, future perspectives for treatment still require
better understanding of its receptors and intracellular path-
way interactions as pain modulators. Therefore, further
translational studies may be performed to address this chal-
lenging topic and design more effective therapies by regu-
lating inﬂammation-induced pain sensation.
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Study
No.
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1 Carlton SM, Du J, Tan HY et al. (2009)
Peripheral and central sensitization in remote
spinal cord regions contribute to central
neuropathic pain after spinal cord injury. Pain
147:265–276
I
2 Chew DJ, Leinster VH, Sakthithasan M et al.
(2008) Cell death after dorsal root injury.
Neurosci Lett 433:231–234
I
3 Czeschik JC, Hagenacker T, Scha ¨fers M et al.
(2008) TNF-alpha differentially modulates
ion channels of nociceptive neurons. Neurosci
Lett 434:293–298
I
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4 DeLeo JA, Colburn RW, Rickman AJ (1997)
Cytokine and growth factor
immunohistochemical spinal proﬁles in two
animal models of mononeuropathy. Brain Res
759:50–57
III
5 DeLeo JA, Rutkowski MD, Stalder AK et al.
(2000) Transgenic expression of TNF by
astrocytes increases mechanical allodynia in a
mouse neuropathy model. Neuroreport
11:599–602
I
6 de Novellis V, Siniscalco D, Galderisi U et al.
(2004) Blockade of glutamate mGlu5
receptors in a rat model of neuropathic pain
prevents early over-expression of pro-
apoptotic genes and morphological changes
in dorsal horn lamina II. Neuropharmacology
46:468–479
I
7 Deumens R, Jaken RJ, Knaepen L et al. (2009)
Inverse relation between intensity of GFAP
expression in the substantia gelatinosa and
degree of chronic mechanical allodynia.
Neurosci Lett 452:101–105
I
8 Gustafson-Vickers SL, Lu VB, Lai AY et al.
(2008) Long-term actions of interleukin-1beta
on delay and tonic ﬁring neurons in rat
superﬁcial dorsal horn and their relevance to
central sensitization. Mol Pain 4:63
II
9 Ignatowski TA, Covey WC, Knight PR et al.
(1999) Brain-derived TNF alpha mediates
neuropathic pain. Brain Res 841:70–77
I
10 Ignatowski TA, Sud R, Reynolds JL et al.
(2005) The dissipation of neuropathic pain
paradoxically involves the presence of tumor
necrosis factor-alpha (TNF).
Neuropharmacology 48:448–460
II
11 Jaken RJ, Joosten EA, Knu ¨wer M et al. (2010)
Synaptic plasticity in the substantia gelatinosa
in a model of chronic neuropathic pain.
Neurosci Lett 469:30–33
II
12 Jiang YQ, Xing GG, Wang SL et al. (2008)
Axonal accumulation of hyperpolarization-
activated cyclic nucleotide-gated cation
channels contributes to mechanical allodynia
after peripheral nerve injury in rat. Pain
137:495–506
II
13 Kawamura T, Akira T, Watanabe M et al.
(1997) Prostaglandin E1 prevents apoptotic
cell death in superﬁcial dorsal horn of rat
spinal cord. Neuropharmacology
36:1023–1030
III
14 Kawasaki Y, Zhang L, Cheng JK et al. (2008)
Cytokine mechanisms of central sensitization:
distinct and overlapping role of interleukin-
1beta, interleukin-6, and tumor necrosis
factor-alpha in regulating synaptic and
neuronal activity in the superﬁcial spinal
cord. J Neurosci 28:5189–5194
I, IV
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15 Kunz S, Tegeder I, Coste O et al. (2005)
Comparative proteomic analysis of the rat
spinal cord in inﬂammatory and neuropathic
pain models. Neurosci Lett 381:
289–293
I, II
16 Li J, Xie W, Zhang JM, Baccei ML (2009)
Peripheral nerve injury sensitizes neonatal
dorsal horn neurons to tumor necrosis factor-
alpha. Mol Pain 5:10
IV
17 Lindenlaub T, Sommer C (2003) Cytokines in
sural nerve biopsies from inﬂammatory and
non-inﬂammatory neuropathies. Acta
Neuropathol 105:593–602
V
18 Liu B, Li H, Brull SJ, Zhang JM (2002)
Increased sensitivity of sensory neurons to
tumor necrosis factor alpha in rats with
chronic compression of the lumbar ganglia.
J Neurophysiol 88:1393–1399
IV
19 Liu YL, Zhou LJ, Hu NW et al. (2007) Tumor
necrosis factor-alpha induces long-term
potentiation of C-ﬁber evoked ﬁeld potentials
in spinal dorsal horn in rats with nerve injury:
the role of NF-kappa B, JNK and p38 MAPK.
Neuropharmacology 52:708–715
I, IV
20 Lu VB, Biggs JE, Stebbing MJ, et al. (2009)
Brain-derived neurotrophic factor drives the
changes in excitatory synaptic transmission in
the rat superﬁcial dorsal horn that follow
sciatic nerve injury. J Physiol 587:1013–1032
I, II
21 Ma W, Quirion R (2001) Increased
phosphorylation of cyclic AMP response
element-binding protein (CREB) in the
superﬁcial dorsal horn neurons following
partial sciatic nerve ligation. Pain 93:295–301
I, II
22 Maione S, Siniscalco D, Galderisi U et al.
(2002) Apoptotic genes expression in the
lumbar dorsal horn in a model neuropathic
pain in rat. Neuroreport 13:101–106
I, II
23 Marchand F, Tsantoulas C, Singh D et al.
(2009) Effects of Etanercept and Minocycline
in a rat model of spinal cord injury. Eur J Pain
13:673–681
VI
24 Milligan ED, Twining C, Chacur M et al.
(2003) Spinal glia and proinﬂammatory
cytokines mediate mirror-image neuropathic
pain in rats. J Neurosci 23:1026–1040
I
25 Moore KA, Kohno T, Karchewski LA et al.
(2002) Partial peripheral nerve injury
promotes a selective loss of GABAergic
inhibition in the superﬁcial dorsal horn of the
spinal cord. J Neurosci 22:6724–6731
II
26 Murata Y, Nannmark U, Rydevik B et al.
(2008) The role of tumor necrosis factor-
alpha in apoptosis of dorsal root ganglion
cells induced by herniated nucleus pulposus
in rats. Spine 33:155–162
IV
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27 Murata Y, Olmarker K, Takahashi I et al.
(2005) Effects of selective tumor necrosis
factor-alpha inhibition to pain-behavioral
changes caused by nucleus pulposus-induced
damage to the spinal nerve in rats. Neurosci
Lett 382:148–152
I
28 Murata Y, Rydevik B, Takahashi K et al.
(2005) Incision of the intervertebral disc
induces disintegration and increases
permeability of the dorsal root ganglion
capsule. Spine 30:1712–1716
II
29 Peng XM, Zhou ZG, Glorioso JC, Fink DJ,
Mata M (2006) Tumor necrosis factor-alpha
contributes to below-level neuropathic pain
after spinal cord injury. Ann Neurol
59:843–851
VI
30 Polga ´r E, Hughes DI, Arham AZ et al. (2005)
Loss of neurons from laminas I–III of the
spinal dorsal horn is not required for
development of tactile allodynia in the spared
nerve injury model of neuropathic pain.
J Neurosci 25:6658–6666
II
31 Scha ¨fers M, Sommer C, Geis C et al. (2008)
Selective stimulation of either tumor necrosis
factor receptor differentially induces pain
behavior in vivo and ectopic activity in
sensory neurons in vitro. Neuroscience
157:414–423
I
32 Scholz J, Broom DC, Youn DH et al. (2005)
Blocking caspase activity prevents
transsynaptic neuronal apoptosis and the loss
of inhibition in lamina II of the dorsal horn
after peripheral nerve injury. J Neurosci
25:7317–7323
II
33 Singh OV, Yaster M, Xu JT, Guan Y, Guan X,
Dharmarajan AM et al. (2009) Proteome of
synaptosome-associated proteins in spinal
cord dorsal horn after peripheral nerve injury.
Proteomics 9:1241–1253
II
34 Siniscalco D, Fuccio C, Giordano C et al.
(2007) Role of reactive oxygen species and
spinal cord apoptotic genes in the
development of neuropathic pain. Pharmacol
Res 55:158–166
II
35 Sommer C, Schmidt C, George A (1998)
Hyperalgesia in experimental neuropathy is
dependent on the TNF receptor 1. Exp Neurol
151:138–142
III
36 Spengler RN, Sud R, Knight PR et al. (2007)
Antinociception mediated by alpha(2)-
adrenergic activation involves increasing
tumor necrosis factor alpha (TNFalpha)
expression and restoring TNFalpha and
alpha(2)-adrenergic inhibition of
norepinephrine release. Neuropharmacology
52:576–589
IV
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37 Sud R, Ignatowski TA, Lo CP, Spengler RN
(2007) Uncovering molecular elements of
brain-body communication during
development and treatment of neuropathic
pain. Brain Behav Immun 21:112–124
II
38 Yamashita M, Ohtori S, Koshi T et al. (2008)
Tumor necrosis factor-alpha in the nucleus
pulposus mediates radicular pain, but not
increase of inﬂammatory peptide, associated
with nerve damage in mice. Spine
33:1836–1842
I
39 Yang L, Zhang FX, Huang F et al. (2004)
Peripheral nerve injury induces trans-synaptic
modiﬁcation of channels, receptors and signal
pathways in rat dorsal spinal cord. Eur J
Neurosci 19:871–883
II
40 Youn DH, Wang H, Jeong SJ (2008)
Exogenous tumor necrosis factor-alpha
rapidly alters synaptic and sensory
transmission in the adult rat spinal cord dorsal
horn. J Neurosci Res 86:2867–2875
IV
I No TNF-a levels measurement, II TNF-a was not involved in
inﬂammatory response, III outdated for the limits of this review; older
than 10 years, IV use of TNF-a as inductor of the lesion or inﬂam-
matory procedure, V clinical study, VI direct central nervous system
injury
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